H.C. Wainwright lowered the firm’s price target on Bicara Therapeutics (BCAX) to $41 from $44 and keeps a Buy rating on the shares following the Q1 report
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX:
- Cautious Outlook on Bicara Therapeutics Inc. Amid Uncertain Pipeline and Market Underperformance
- Bicara Therapeutics Reports Q1 2025 Financial Results
- Promising Clinical Progress and Strategic Expansion Drive Buy Rating for Bicara Therapeutics
- Promising Potential of Bicara Therapeutics’ Ficera: A Buy Rating Backed by Strong Clinical Data and Innovative Approach
- Bicara Therapeutics reports Q1 EPS (68c), consensus (40c)